Search This Blog

Tuesday, February 3, 2026

Newsom gives ice cold take on marriage to Kimberly Guilfoyle: ‘Going through the motions’

 California Gov. Gavin Newsom admits he was a cold, distant husband to first wife Kimberly Guilfoyle – writing in his forthcoming memoir he was “just going through the motions.”

Newsom said he married Guilfoyle at a time when he became “skilled at repressing my feelings,” according to an excerpt of the memoir, “Young Man in a Hurry,” which drops Feb. 24.

“Kimberly allowed me this emotional distance,” the Democratic governor wrote in the memoir, according to The New York Times

California Gov. Gavin Newsom admits he was a cold, distant husband to first wife Kimberly Guilfoyle.REUTERS
Newsom said he married Guilfoyle at a time when he became “skilled at repressing my feelings.”ASSOCIATED PRESS

The pair, once considered “the New Kennedys,” were married in 2001 when Newsom was serving as the mayor of San Francisco. 

But, the courtship seemed more contractual than intimate. 

Newsom described the moments leading up to “I do,” as simply going “through all the motions until the motions led me right up to the altar,” the paper reported. 

Guilfoyle, who went on to date Donald Trump, Jr. and is now the US Ambassador to Greece, filed for divorce from Newsom in 2005 citing the demands of their respective careers while living on opposite coasts. 

It was later revealed that as the couple were breaking up, Newsom had an affair with his then-deputy chief of staff’s wife, a moment of infidelity he described in his book as “the worst betrayal of my life.”

Newsom described the moments leading up to “I do,” as simply going “through all the motions.”WireImage

“I thought of myself as a single guy who happened to be mayor,” Newsom wrote, according to the paper. “Had my head been on straight, I would have seen it was the other way around.”

Newsom, however, reportedly opted out of discussing some of his other love interests — including 19-year-old model and college lacrosse star Brittanie Mountz whom he dated when he was 38-years old.

Newsom — a potential Democratic presidential candidate in 2028 — dismissed that fling to the Times, claiming that the mismatched pair “only went on a few dates.”

He also said in the book that he broke up with “The Sopranos” and “CSI” actress Sofia Milos at the behest of oil magnate Gordon Getty, who told him she “wasn’t suited to him.”

https://nypost.com/2026/02/03/us-news/gavin-newsom-was-just-going-through-the-motions-in-marriage-to-kimberly-guilfoyle/

US Shutdown To End As House Approves Trump-Negotiated Funding Deal

 Update (1410ET): As was somewhat expected, the partial US government shutdown is on track to end later today after the House passed a funding deal President Trump negotiated with Senate Democrats, overcoming opposition from both ends of the political spectrum.

A group of conservatives had threatened to use procedural maneuvers to blockade the deal but relented after Trump demanded they vote to pass the measure.

“The president nailed it down,” House Appropriations Committee Chairman Tom Cole, an Oklahoma Republican, told reporters.

“I’m glad we are all nails and there’s one hammer.”

The House vote was 217 to 214.

The spending package, which Trump has said he wants enacted quickly, now goes to the president for his signature.

*  *  *

The U.S. House of Representatives on Tuesday will take up a bill to fund several sectors of the federal government as a partial shutdown enters its fourth day.

Many Democrats - including leaders - have vowed to withhold support from the package.

On Monday evening, the House Committee on Rules advanced the measure - which would fully fund five sectors of the government while extending funding for the Department of Homeland Security (DHS) until Jan. 13 - in a party-line 8–4 vote following a more than four-hour committee hearing.

As Jopseph Lord and Nathan Worcester report for The Epoch Timeswith Democratic leaders indicating that they won’t give their backing to the measure, House Speaker Mike Johnson (R-La.) will need to rely mostly on his narrow Republican majority to pass the measure.

In a full vote of the House, Johnson can spare only one defection in a party-line vote, though some Democrats are expected to back the measure.

However, some issues with the Senate proposal could lead Republicans to oppose the measure.

Rep. Thomas Massie (R-Ky.), a longtime budget hawk and a particular opponent of the Cybersecurity and Infrastructure Security Agency (CISA), which falls under DHS, voted against the previous funding measure due to its funding for CISA, and could oppose the stopgap measure as well.

Other Republicans have pushed leadership to attach the Safeguarding American Voter Eligibility (SAVE) Act to the measure.

Leadership has resisted these demands, which Senate Minority Leader Chuck Schumer (D-N.Y.) says would make the bill dead on arrival in the upper chamber. The bill reported out of the Rules Committee didn’t include the SAVE Act.

Nevertheless, the passage of the legislation through the Rules Committee—which includes conservative skeptics of the bill such as Reps. Ralph Norman (R-S.C.) and Chip Roy (R-Texas)—is a good sign for Republican leaders on the funding package’s prospects.

House Majority Leader Steve Scalise (R-La.) downplayed the difficulties in comments to reporters on Monday.

“They all come down to the wire, and then we get our business done,” Scalise said.

The bill at issue would provide full-year funding for the departments of Defense, Labor, Health and Human Services, Education, Transportation, and Housing and Urban Development.

Democrats are demanding reforms to DHS and its subsidiary immigration enforcement agencies before they’ll support a full-year funding measure, though many House Democrats—including leadership—have expressed opposition to extending DHS funding at all before these reforms are addressed.

Rules Committee Ranking Member Jim McGovern (D-Mass.), meanwhile, voiced opposition to the measure at the hearing.

“I will not vote for business as usual while masked agents break into people’s homes without a judicial warrant, in violation of the Fourth Amendment,” he said, referencing ongoing disputes related to the executive branch’s use of self-issued administrative warrants, rather than court-issued judicial warrants, to enter homes.

However, one Democrat—House Appropriations Committee Chairwoman Rosa DeLauro (D-Conn.)—indicated at the hearing that she would break with her party to back the measure.

“I will support this package,” DeLauro said at the hearing, referencing the five full-year funding bills attached to the package that have Democratic support.

She said that without the funding extension for DHS, Democrats “won’t be able to bring the kinds of pressure” needed to add reforms to the full-year DHS funding package.

McGovern explained his opposition in response to a question from The Epoch Times outside the hearing room.

“Personally, [I] cannot bring myself to go for one more cent for ICE without some serious guardrails put in place, and I think the leverage we have is now more so than two weeks from now,” McGovern said.

Johnson has said he is “confident” that the partial shutdown will end with the Tuesday vote, despite indicating that House Democrats haven’t given their support to pass the Senate-passed measure.

“We have a logistical challenge of getting everyone in town, and because of the conversation I had with Hakeem Jeffries, I know that we’ve got to pass a rule and probably do this mostly on our own,” Johnson told NBC News’s “Meet the Press.”

House Democratic leadership has not indicated support for the measure publicly, despite it having been backed by Schumer and other Senate Democrats.

House Minority Leader Hakeem Jeffries (D-N.Y.) told ABC’s “This Week” that it’s clear that the “Department of Homeland Security needs to be dramatically reformed.”

“Masks should come off,” he said. “Judicial warrants should absolutely be required consistent with the Constitution, in our view, before DHS agents or ICE agents are breaking into the homes of the American people or ripping people out of their cars.”

https://www.zerohedge.com/political/house-vote-package-end-partial-shutdown

Third Georgia Democrat Lawmaker Accused Of Pandemic Fraud

 A Democrat member of the Georgia House of Representatives was charged Friday with lying to obtain thousands of dollars in emergency pandemic unemployment assistance, according to federal prosecutors - the third Democrat in the Georgia House to be accused of doing so. 

Rep. Dexter Sharper, 54

Dexter Sharper, 54, of Valdosta, is accused of falsely claiming he was unemployed while collecting benefits intended to those who had lost their jobs during the COVID-19 pandemic. Sharper allegedly received $13,825 in unemployment assistance between April 2020 and May 2021, while continuing to earn income from various sources

"While many of his constituents and fellow citizens were losing jobs and desperately needed unemployment assistance during the pandemic, Representative Sharper allegedly pretended to be out of work to collect a share of unemployment benefits for himself," said US Attorney Theodore S. Hertzberg. 

Court records reveal that Sharper certified in 38 weekly filings that he was unemployed and was actively seeking employment. Investigators say he was lying and continued to receive weekly pay from the Georgia General Assembly, as well as from his party rental business - with additional income as a musician

“These charges point to some disgraceful conduct at the highest level, which should shock and repulse every citizen”, said Georgia State Inspector General Nigel Lange. “The alleged activities describe a disgusting abuse by an elected official who appeared to trade his integrity for money destined for those in need. Shameful.” 

Two other Democratic state reps have been indicted on similar charges related to pandemic unemployment fraud;

In December, Rep. Sharon Henderson was charged with two counts of theft of government funds and 10 counts of making false statements, resulting in her suspension last week by Gov. Brian Kemp. 

Rep. Sharon Henderson (D)

Meanwhile, Rep. Karen Bennett resigned from office two days before she was charged and pleaded guilty to making false statements earlier in January. 

Rep. Karen Bennett (D)

Birds of a feather, eh? 

https://www.zerohedge.com/political/third-georgia-democrat-lawmaker-accused-pandemic-fraud

Pfizer sets sights on R&D strategy amid modest FY25 results

 New York-based pharma giant Pfizer has met targets for its fiscal year 2025 (FY25) financials, which come as the company looks to refresh its portfolio amid looming patent losses and waning Covid vaccine sales.

In FY25, Pfizer generated full-year revenues of $62.6bn. While this meets the company’s previously adjusted FY25 profit forecast of $62bn, it represents a 2% operational decline compared to FY24. Earnings per share (EPS) were in line with Citi analyst consensus, standing at $1.36, although they were lower than the 2024 rate of $1.41.

The company also reaffirmed its 2026 financial guidance, with revenues between $59.5bn and $62.5bn expected, with a diluted EPS range of $2.80 to $3.00.

The results follow a tough 2025 for Pfizer, in which the company has battled with declining Covid-19 vaccine sales and the upcoming loss of exclusivity impacting several key drugs in its portfolio, including Janus kinase (JAK) inhibitor, Xeljanz (tofacitinib). Currently, Pfizer forecasts that patent expiries will result in $1.5bn of revenue losses in FY26.

Despite this overall loss, 2025 revenues were looking more favourable when Covid-19 vaccines Paxlovid (nirmatrelvir/ritonavir) and Comirnaty (Covid-19 vaccine, mRNA) were discounted from the equation – with the rest of the company’s pipeline achieving operational growth of 6%.

Within its wider primary care portfolio, Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo was a strong driver of growth, bringing in $1bn across the global market – up 37% from the $755m in total sales achieved in FY24. This offset the 9% total revenue decline observed in the US, which comes amid the Trump administration’s continued efforts to alter vaccine policy. Sanofi’s RSV jab, Beyfortus (nirsevimab), experienced a similar, but steeper decline in US sales during FY2025.

Pfizer and Bristol Myers Squibb’s (BMS) best-selling blood thinner, Eliquis (apixaban), also had a good year, posting an 8% sales increase compared to 2024, with $7.96bn in total sales for 2025. However, this may be one of the last years of consistent growth for the factor Xa blocker, as its key patents are set to expire between 2027 and 2029.

Within its oncology portfolio, Pfizer touted positive financial results from its antibody-drug conjugate (ADC) Padcev (enfortumab vedotin), which made 22% more than 2024 by generating global sales of $1.94bn. It was a similar story for anaplastic lymphoma kinase (ALK) inhibitor Lorbrena (lorlatinib), which hit blockbuster status while demonstrating YoY growth of 40%.

Despite these wins, investors do not appear to be best pleased with Pfizer’s overall FY25 sales outcome, as the pharma’s stock value dropped by 4.9% from $26.66 at market close on 2 February to $25.36 at market open on 3 February after the results debuted. The New York-based pharma has a market cap of $144.4bn.

R&D to foster future growth

In an investor call held on 3 February, Pfizer’s CEO, Albert Bourla, touted 2026 as a “key catalyst” for the company’s future growth up to 2030, noting that the initiation of 20 key pivotal studies will help “maximise opportunities” for the company.

At the recent 2026 J.P. Morgan Healthcare Conference in San Francisco, Bourla shared Pfizer’s plans to deliver a “catalyst-rich R&D agenda,” while maximising the value of its recent transactions – including its $10bn buyout of obesity biotech, Metsera.

This deal already appears to be reaping benefits for Pfizer, as its newly acquired, once-monthly glucagon-like peptide 1 receptor agonist (GLP-1RA), PF3994, met its primary trial endpoint of significant weight reduction at 28 weeks during the Phase IIb VESPER-3 study (NCT06973720).

The therapy, which was previously known as MET-097i, is now expected to enter 10 Phase III trials in 2026 across the obesity space.

In a research note, Citi analysts noted that they were most compelled by the successful transition to a monthly dosing schedule, as well as the continued weight loss trajectory with no observed plateau, which they say could “reinforce confidence in the asset’s potential”.

To help fund studies on its clinical pipeline, Bourla noted that Pfizer has been, and will continue to create cost savings within R&D and across the wider business through the deployment of artificial intelligence (AI). Adding to Bourla’s point, Chris Boshoff, CSO and president of R&D, says the company is “recruiting and embedding AI engineers” across discovery, medical regulatory, safety, pharmacovigilance and clinical trial execution to “measure success, productivity, speed and costs”.

https://www.pharmaceutical-technology.com/news/pfizer-fy25-results-future-directions-obesity-ai/

Invivyd rises as FDA agrees with late-stage trial design for COVID-19 therapy

 Invivyd (IVVD) stock rises as FDA aligns on LIBERTY Phase 3 trial for the company's antibody therapy VYD2311 in COVID prevention.

https://seekingalpha.com/news/4546213-invivyd-rises-fda-agrees-with-covid-trial

HOOKIPA Pharma (HOOK) Divests Key Immuno-Oncology Assets

 HOOKIPA Pharma, identified by the ticker HOOK, has announced plans to divest its key immuno-oncology assets to NeoTrail Therapeutics. This transaction includes primarily the HB-200 and HB-700 development programs. Although the financial details of this sale have not been disclosed, the agreement was officially signed on January 28, 2026. The deal is anticipated to be finalized in the second quarter of 2026, contingent upon the fulfillment of customary closing conditions.

https://www.gurufocus.com/news/8577709/hookipa-pharma-hook-divests-key-immunooncology-assets

'FDA rejects AZ's subQ Saphnelo, but company expects quick turnaround for new approval decision'

 AstraZeneca has hit what appears to be a minor speed bump in gaining clearance in the U.S. for its subcutaneous (SC) version of lupus treatment Saphnelo.

The FDA has sent the British drugmaker a complete response letter, rejecting its application that would allow patients to self-administer the monoclonal antibody by way of a prefilled pen, the drugmaker said in a Feb. 3 press release. 

While AZ did not specify the reason for the rejection, it did say that it has provided information the regulator requested and is “committed to working with the FDA to progress the application as quickly as possible.”

Even with the CRL, the company said it still expects a decision on its updated Saphnelo SC application in the first half of this year.

The rejection comes after the European Medicines Agency signed off on the prefilled pen in December. The advancement gives patients a convenient alternative to traveling to a doctor's office for infusions every four weeks.

It also comes after AZ strengthened its case for approval last month, presenting results from a trial that showed Saphnelo SC provided a statistically significant and clinically meaningful reduction in disease activity compared with placebo, with an efficacy and safety profile consistent with its intravenous version of Saphnelo, the company said. The study also showed that the treatment helped patients reduce their use of oral corticosteroids.

There was little reaction in the market to the setback as AZ’s share price increased by less than 1% on Tuesday morning.

The FDA originally approved Saphnelo in 2021 as the first new treatment in a decade for systemic lupus erythematosus (SLE) and a challenger to GSK’s Benlysta. The U.K. rival gained an FDA nod for its subcutaneous version of Benlysta in 2017.

GSK's BlyS inhibitor generated sales of 2.7 billion pounds sterling ($3.7 billion) in the first nine months of 2025, compared with $483 million for Saphnelo in the same period. GSK’s sales of Benlysta have also been impacted positively by label expansions starting in 2020 to treat lupus nephritis. 

More than 3.4 million people in the world have SLE. It primarily affects women, causing pain, rashes, fatigue, swelling in joints and fevers. In Europe, people with SLE have a two to three times increased risk of death compared to the overall population, AZ has said. Oral corticosteroids provide relief but do not target the underlying drivers of the disorder.

Meanwhile, Spherix Global Insights analysts note that the lupus treatment landscape is “poised for evolution,” citing Biogen’s experimental litifilimab as an “especially strong competitor” to Benlysta and Saphnelo.

AZ gained worldwide rights to Saphnelo in a 2004 licensing and collaboration agreement with Medarex, which was acquired by Bristol Myers Squibb in 2009. Under the agreement, which was updated last year, AstraZeneca pays BMS a mid-teens royalty on U.S. sales.

https://www.fiercepharma.com/pharma/fda-gets-under-az-skin-rejection-its-subcutaneous-version-saphnelo